Lactose, Anhydrous

Summary

Lactose, Anhydrous (CHEMBL5314358) is a phase-3 clinical-stage unknown targeting P2RX4 and SLC6A4; indicated across 24 conditions including diarrheal disease and metabolic dysfunction-associated steatotic liver disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Targets: 2 (P2RX4, SLC6A4)
• Indications: 24 conditions
• Clinical trials: 73

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314358
Name	Lactose, Anhydrous
Type	Unknown
Max phase	3

Also known as: Anhydrous lactose, Lactopress anhydrous, Lactose, Lactose anhydrous, anhydrous, Lactose-electricitas, Lactosum, Saccharum lactis, Supertab 21an, Supertab 22an, Supertab 24an, lactose

Parent form; salt/anhydrous children: CHEMBL5498481

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
P2RX4	P2X4	Antagonist	6	1.2%	Q99571
SLC6A4	SERT	Inhibition	10.1	0.7%	P31645

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Galectin-3, Galectin-9, Galectin-8.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): P2RX4, SLC6A4.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Neurotransmitter clearance	1	SLC6A4
Transmission across Chemical Synapses	1	SLC6A4
Neuronal System	1	SLC6A4
Elevation of cytosolic Ca2+ levels	1	P2RX4
Serotonin clearance from the synaptic cleft	1	SLC6A4
Platelet homeostasis	1	P2RX4
SLC-mediated transport of neurotransmitters	1	SLC6A4
Purinergic signaling in leishmaniasis infection	1	P2RX4

Dominant GO biological processes

GO term	Targets
membrane depolarization	2
tissue homeostasis	1
regulation of sodium ion transport	1
response to ischemia	1
signal transduction	1
regulation of blood pressure	1
positive regulation of calcium ion transport into cytosol	1
negative regulation of cardiac muscle hypertrophy	1
sensory perception of pain	1
calcium-mediated signaling	1
positive regulation of prostaglandin secretion	1
response to ATP	1
monoatomic ion transmembrane transport	1
response to fluid shear stress	1
purinergic nucleotide receptor signaling pathway	1

Indications & clinical

Indications

24 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diarrheal disease	3	MONDO:0001673	HP:0002014
metabolic dysfunction-associated steatotic liver disease	3	MONDO:0013209	EFO:0003095
Raynaud disease	3	MONDO:0008364	EFO:1001145
vitamin D deficiency	3	MONDO:0100471	EFO:0003762
bone fracture	3	MONDO:0005315	EFO:0003931
asthma	3	MONDO:0004979	MONDO:0004979
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
tuberculosis	3	MONDO:0018076	MONDO:0018076
gastroesophageal reflux disease	2	MONDO:0007186	EFO:0003948
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
acute lung injury	2	MONDO:0015796	EFO:0004610
bronchiolitis obliterans syndrome	2	MONDO:0015265	EFO:0007183
acute respiratory distress syndrome	2	MONDO:0006502	EFO:1000637
cocaine dependence	2	MONDO:0005186	EFO:0002610
nicotine dependence	2	MONDO:0008575	EFO:0003768
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
opiate dependence	2	MONDO:0005530	EFO:0005611
Paramyxoviridae infectious disease	2	MONDO:0005896	EFO:0007419
overactive bladder	2	MONDO:0006624	EFO:1000781
enuresis	2	MONDO:0024290	MONDO:0024290
post-traumatic stress disorder	2	MONDO:0005146	EFO:0001358
migraine disorder	2	MONDO:0005277	MONDO:0005277
periodontitis	0	MONDO:0005076	EFO:0000649

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 73.

Phase distribution

Phase	Trials
Not specified	28
PHASE2	21
PHASE4	10
PHASE3	9
PHASE1	3
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00361543	PHASE4	COMPLETED	Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
NCT00841230	PHASE4	COMPLETED	Deanxit and Rivotril in Tinnitus Patients
NCT01014338	PHASE4	COMPLETED	Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)
NCT01041755	PHASE4	COMPLETED	Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
NCT01151306	PHASE4	COMPLETED	The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01550107	PHASE4	COMPLETED	Allopurinol in Functional Impairment (ALFIE) Trial: ‘Improving Muscle Strength’
NCT01748279	PHASE4	COMPLETED	The Effects of Atorvastatin Treatment in COPD Patients
NCT02286960	PHASE4	COMPLETED	Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes
NCT02636413	PHASE4	COMPLETED	Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance
NCT03497598	PHASE4	TERMINATED	Preventing Recurrent Urinary Tract Infections With α-D-mannose
NCT06618573	PHASE2/PHASE3	RECRUITING	Safety of Administering Isoniazid to SLE Patients to Prevent TB
NCT00351117	PHASE3	COMPLETED	St. John’s Wort in the Treatment of Raynaud’s Phenomenon
NCT00504946	PHASE3	COMPLETED	Pharmacological Modulations of Allergen-Specific Immunotherapy
NCT00507000	PHASE3	UNKNOWN	Pulmonary Tuberculosis and Vitamin D
NCT00623285	PHASE3	UNKNOWN	The Effects of Peri-operative Pregabalin Administration on Post-operative Analgesia in Patients Undergoing Coronary Bypass Grafting
NCT00979056	PHASE3	COMPLETED	Prophylactic Treatment of Travellers’ Diarrhoea With Rifaximin
NCT01190683	PHASE3	COMPLETED	Vitamin D and Muscle Strength and Surface (Electromyography) EMG
NCT01277237	PHASE3	COMPLETED	The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
NCT03582176	PHASE3	COMPLETED	PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2
NCT04237090	PHASE3	COMPLETED	Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
NCT00149630	PHASE2	COMPLETED	Pharmacogenetics of Disulfiram for Cocaine
NCT00624754	PHASE2	COMPLETED	Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT
NCT00888680	PHASE2	WITHDRAWN	Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
NCT01040429	PHASE2	COMPLETED	The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial
NCT01136317	PHASE2	COMPLETED	Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects
NCT01400906	PHASE2	COMPLETED	Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
NCT01504867	PHASE2	COMPLETED	LIPS-A: Lung Injury Prevention Study With Aspirin
NCT01575678	PHASE2	UNKNOWN	The Effect of Melatonin on Nocturnal Enuresis
NCT01644877	PHASE2	COMPLETED	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
NCT01659307	PHASE2	COMPLETED	The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury
NCT01675986	PHASE2	COMPLETED	Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score
NCT02042521	PHASE2	COMPLETED	A Dietary Supplement for Early Cigarette Withdrawal
NCT02086864	PHASE2	COMPLETED	A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD
NCT02326350	PHASE2	TERMINATED	ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial
NCT02787707	PHASE2	COMPLETED	Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting
NCT02999022	PHASE2	UNKNOWN	Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)
NCT03063931	PHASE2	UNKNOWN	Pain and Magnesium
NCT03121222	PHASE2	COMPLETED	The Effects of N-acetylcysteine on Performance and Redox Homeostasis
NCT03423667	PHASE2	TERMINATED	Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction
NCT03464708	PHASE2	UNKNOWN	A Study to Investigate the Effect of HMB on Skeletal Muscle Wasting in Early Critical Illness

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

447 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
PAROXETINE	ChEMBL + PubChem	Phase 4 (approved)	P2RX4, SLC6A4
DULOXETINE	ChEMBL	Phase 4 (approved)	P2RX4, SLC6A4
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
TADALAFIL	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
UMECLIDINIUM	ChEMBL + PubChem	Phase 4 (approved)	SLC6A4
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	SLC6A4
ACRIVASTINE	ChEMBL	Phase 4 (approved)	SLC6A4
ALECTINIB	ChEMBL	Phase 4 (approved)	SLC6A4
ALLOPURINOL	ChEMBL	Phase 4 (approved)	SLC6A4
AMBENONIUM	ChEMBL	Phase 4 (approved)	SLC6A4
AMIODARONE	ChEMBL	Phase 4 (approved)	SLC6A4
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	SLC6A4
AMPHOTERICIN B	ChEMBL	Phase 4 (approved)	SLC6A4
APOMORPHINE	ChEMBL	Phase 4 (approved)	SLC6A4
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
ASENAPINE	ChEMBL	Phase 4 (approved)	SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
ATOMOXETINE	ChEMBL	Phase 4 (approved)	SLC6A4
ATRACURIUM	ChEMBL	Phase 4 (approved)	SLC6A4
AZATHIOPRINE	ChEMBL	Phase 4 (approved)	SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	SLC6A4
BALSALAZIDE	ChEMBL	Phase 4 (approved)	SLC6A4
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	SLC6A4
BENFLUOREX	ChEMBL	Phase 4 (approved)	SLC6A4
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BENZTROPINE	ChEMBL	Phase 4 (approved)	SLC6A4
BENZYDAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BEPRIDIL	ChEMBL	Phase 4 (approved)	SLC6A4
BOSUTINIB	ChEMBL	Phase 4 (approved)	SLC6A4
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	SLC6A4
BROMHEXINE	ChEMBL	Phase 4 (approved)	SLC6A4
BROMODIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BROMPERIDOL	ChEMBL	Phase 4 (approved)	SLC6A4
BROMPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
BUPROPION	ChEMBL	Phase 4 (approved)	SLC6A4
BUTENAFINE	ChEMBL	Phase 4 (approved)	SLC6A4
CABERGOLINE	ChEMBL	Phase 4 (approved)	SLC6A4
CALCIPOTRIENE	ChEMBL	Phase 4 (approved)	SLC6A4
CALCITRIOL	ChEMBL	Phase 4 (approved)	SLC6A4
CANAGLIFLOZIN	ChEMBL	Phase 4 (approved)	SLC6A4
CARBINOXAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CARVEDILOL	ChEMBL	Phase 4 (approved)	SLC6A4
CEFONICID	ChEMBL	Phase 4 (approved)	SLC6A4
CELECOXIB	ChEMBL	Phase 4 (approved)	SLC6A4
CETIRIZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPHENTERMINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	SLC6A4
CINNARIZINE	ChEMBL	Phase 4 (approved)	SLC6A4
CISAPRIDE	ChEMBL	Phase 4 (approved)	SLC6A4
CITALOPRAM	ChEMBL	Phase 4 (approved)	SLC6A4